Alembic Pharmaceuticals Limited · NSE:APLLTD

Alembic Pharmaceuticals — Q3 FY22 Earnings Presentation

15 slides from Alembic Pharmaceuticals's earnings presentation, December 2021

1. Slide 1: Alembic Pharmaceuticals Limited Investor presentation – December 2021

   Alembic Pharmaceuticals Limited Investor presentation – December 2021 BSE & NSE: APLLTD

2. Slide 2: Milestones

   Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2009 Multiple divisions to address chronic therapies launched 2010 Pharmaceuticals business demerged from Alembic – APL

3. Slide 3: Financial Highlights

   Financial Highlights INR Bn Particulars Q3 FY22 Q3 FY21 Growth 9M FY22 9M FY21 Growth FY21 Net Sales 12.72 13.14 -3% 38.90 41.13 -5% 53.93 EBIDTA Pre R&D 4.06 5.36 -24% 12.33 17.13 -28% 22.52 Margin % 32% 41% 32% 42% 42% R&D 1.53 1.48 4% 4.89 4.75 3% 6.70 R&D % 12% 11% 13% 12% 12% EBIDTA Post R&D 2.

4. Slide 4: Business snapshot – Q3FY22

   Business snapshot – Q3FY22 Formulations Generics Branded API Total US Ex-US India Revenue Q3FY22 (INR Bn) 3.93 1.93 4.88 1.98 12.72 API Vet 16% 16% 31% 5% Generics Q3FY22 Revenue 46% Acute Contribution 14% Branded 15% 38% Speciality 20% Growth Q3FY22 -23% -7% -3% 13% 17% over Q3FY21 Growth Q3FY22 -2

5. Slide 5: Business snapshot – YTDFY22

   Business snapshot – YTDFY22 Formulations Generics Branded API Total US Ex-US India Revenue YTDFY22 (INR Bn) 11.09 5.87 14.78 7.16 38.90 API Vet 18% 18% 5% Generics YTDFY22 Revenue 29% 44% Contribution Acute 14% 15% Branded Speciality 19% 38% Growth YTDFY22 -34% -3% -5% 8% 30% over YTDFY21 • Well-est

6. Slide 6: US Generic

   US Generic INR Bn Revenue – Q3 FY22 INR Bn Revenue – Last 5 Years CAGR - 24% 5.12 19.76 21.63 3.93 12.88 9.19 9.20 Q3FY21 Q3FY22 FY17 FY18 FY19 FY20 FY21 Approved ANDAs Injectable Derma 2 Inhalation 18 1 ➢ Increase in competitive intensity during YTDFY22 which has led to price erosion in few large p

7. Slide 7: Ex-US Generics

   Ex-US Generics Revenue : Q3 FY22 INR Bn Revenue – Last 5 Years INR Bn CAGR - 25% 1.93 1.71 7.79 4.94 4.97 Q3FY21 Q3FY22 ➢ The Ex-US business continuous to do well in spite of a high base last 3.20 2.86 year. ➢ The Ex-US business grew at 8% during YTDFY22. ➢ New launches on track to drive growth in t

8. Slide 8: API

   API Revenue : Q3 FY22 INR Bn Revenue – Last 5 Years INR Bn CAGR - 11% 2.14 1.98 9.55 7.71 7.08 6.40 6.51 Q3FY21 Q3FY22 ➢ API business continues to do well. Last year had a high base of Azithromycin and hence business de-grew by 7% and 3% during Q3FY22 and YTDFY22, respectively. ➢ Rest of the portfol

9. Slide 9: R&D Significant investments in building capabilities

   R&D Significant 10.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 37 Filing 8.0 13.7% 14.0% Approval 13.1% 12.7% 29 30 29 12.4% 6.0 25 R&D Spend 20 19 20 18 * 11 Filings & 4.0 6.7 7 Approvals 6.5 R&D % of were 5.0 sales 2.0 4.3 4.1 contributed by 5 acquisition o

10. Slide 10: State of the art facilities and infrastructure

    State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Mar’20* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables Feb’21# F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Nov’2

11. Slide 11: Branded Business

    Branded Business Revenue – Q3 FY22 INR Bn Revenue – Last 5 Years CAGR - 5% INR Bn 15.0 4.88 13.8 14.3 4.18 12.7 0.61 12.5 0.50 Vet 1.74 1.42 Acute Speciality 2.25 2.53 Q3FY21 Q3FY22 FY17 FY18 FY19 FY20 FY21 Marketing organization Key achievements ➢ 5500 + Marketing team ➢ 3 Brands in top 300 ➢ 18 Ma

12. Slide 12: Therapy-wise Performance Q3 FY22

    Therapy-wise Performance Q3 FY22 Q3 FY22 Q3 FY21 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 8 1.9 5 7 15 1.9 15 16 Gastrology 13 1.4 14 14 13

13. Slide 13: Therapy-wise Performance YTD FY22

    Therapy-wise Performance YTD FY22 FY22 FY21 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 11 1.8 6 10 14 1.9 15 14 Gastrology 21 1.4 24 21 3 1.4

14. Slide 14: Financials : Generating consistent returns

    Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 53.93 16.31 11.78 46.06 39.35 12.13 8.29 31.34 31.31 8.75 5.84 6.15 6.42 4.13 4.03 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 CAGR - 15% CAGR - 28% CAGR - 31% EBIDTA margin % Cap

15. Slide 15: Thank you

    Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu

Alembic Pharmaceuticals — Q3 FY22 Earnings Presentation on 6ix